骨靶向放射性核素治疗肺癌骨转移疼痛的研究进展  

Research progress in bone-targeting radionuclides in the treatment of bone metastases from lung cancer

作　　者：何平[1] 杜明华[1] He Ping;Du Minghua(Department of Nuclear Medicine,Jiangsu Province Hospital of Chinese Medicine,Nanjing 210029,China)

机构地区：[1]江苏省中医院核医学科,南京210029

出　　处：《国际放射医学核医学杂志》2020年第3期189-195,共7页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：南京市科技基金(201715006)。

摘　　要：肺癌骨转移是肿瘤晚期的常见并发症,患者由于严重的疼痛往往导致生活质量下降,且易出现与骨骼相关的不良事件,如病理性骨折、脊髓压迫和高钙血症等.针对轻、中度骨转移引起的疼痛可以采用常规止痛、镇痛和外部照射放疗.但在全身多处转移和疼痛严重的情况下,以上3种方法的疗效都不好,且不良反应严重.而某些放射性核素能够特异性地被活性增高的成骨细胞摄取,并且能较长时间滞留于骨组织中.因此,使用一些新型骨靶向放射性核素,如89Sr、153Sm和186Re等进行系统性的治疗成为新型方式,为肺癌骨转移疼痛的治疗提供了更多的靶点和安全有效的手段.Bone metastasis is a common complication of advanced tumors.Severe pain frequently leads to a decline in quality of life and tendency toward bone-related adverse events,such as pathological fractures,spinal cord compression,and hypercalcemia.To alleviate pain caused by mild to moderate bone metastases,conventional analgesic or external radiation therapy can be used.However,when multiple body metastases and severe pain occur,the two aforementioned methods become ineffective and cause serious side effects.Some radionuclides can be specifically taken up by activated osteoblasts and can be retained in bone tissues for a long time.Therefore,systematic treatment with several new bone-targeting radionuclides,such as 89Sr,153Sm,and 186Re,has become a new approach for providing additional targets and a safe and effective treatment for bone metastases.

关 键 词：肺肿瘤 放射性核素治疗 疼痛 骨转移 

分 类 号：R734.2[医药卫生—肿瘤]